Berberine vs PT-141
Moderate Research vs FDA Approved
monitor Mechanism-based · 51% Both Berberine and PT-141 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Berberine PT-141
Weight 336.36 Da —
Half-life ~4 hours ~2.7 hours
Type Isoquinoline alkaloid (C20H18NO4+) Melanocortin receptor agonist
Key Benefits
Berberine
01 Activation of AMPK, improving cellular energy metabolism and glucose utilization
02 Clinically demonstrated reductions in fasting blood glucose and HbA1c comparable to metformin in some trials
03 Improved lipid profiles with reductions in total cholesterol, LDL cholesterol, and triglycerides
04 Enhanced insulin sensitivity through upregulation of insulin receptor expression
05 PCSK9 inhibition leading to improved LDL cholesterol clearance
06 Gut microbiome modulation favoring beneficial short-chain fatty acid-producing bacteria
07 Anti-inflammatory effects via NF-kB pathway suppression
08 Available over the counter as a dietary supplement without prescription
PT-141
01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)
Dosing Protocols
Berberine
500 mg 2-3x/day / 2-3x daily with meals
PT-141
Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance / As needed before sexual activity; max 1 dose per 24 hours
Female HSDD (FDA-approved) 1.75mg As needed, max 1 dose/24hr
Male Erectile Dysfunction 1-2mg As needed, 45-60min before activity
Female Arousal Disorder 0.75-1.25mg As needed, max 1 dose/24hr
Low Starting Dose 0.5mg Test dose for tolerance assessment
Side Effects
Berberine
Gastrointestinal distress (diarrhea, cramping, bloating, nausea, flatulence) - most frequent complaint, affecting 10-15% of users, especially at higher doses or without food
Constipation (less common than diarrhea but reported by some users)
Decreased appetite
Mild abdominal discomfort, particularly during the first 1-2 weeks of use
PT-141
Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Contraindications
Pregnancy and breastfeeding (berberine may stimulate uterine contractions and crosses into breast milk)
Neonates and young children (risk of kernicterus - berberine can displace bilirubin from albumin)
Severe hepatic impairment
Concurrent use with medications that have narrow therapeutic indices metabolized by CYP3A4 (e.g., cyclosporine, tacrolimus) without close medical supervision
Known hypersensitivity to berberine or berberine-containing plants
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding
Research Evidence
Berberine PT-141
Status Moderate Research FDA Approved
References 5 studies 4 studies
Latest 2023 2022
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.